Quarterly ResultMay 12, 2026, 08:37 AM
Veradermics VDPHL01 Phase 2/3 Positive; Raises $766.8M; Q1 Net Loss $27.2M
AI Summary
Veradermics, Inc. reported positive topline results from its Phase 2/3 Study ‘302’ for VDPHL01, an oral treatment for pattern hair loss, showing robust hair growth and a favorable safety profile. This positions VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years. The company also successfully raised approximately $766.8 million through an upsized IPO and follow-on financing, extending its cash runway into 2030. For Q1 2026, Veradermics reported a net loss of $27.2 million, an increase from $12.4 million in Q1 2025, driven by higher R&D and G&A expenses.
Key Highlights
- VDPHL01 Phase 2/3 Study ‘302’ showed positive topline results for male pattern hair loss.
- Raised approximately $766.8 million in gross proceeds from IPO and follow-on offerings.
- Cash, cash equivalents, and marketable securities totaled $390.8 million as of March 31, 2026.
- Net loss for Q1 2026 was $27.2 million, compared to $12.4 million in Q1 2025.
- R&D expenses increased to $20.9 million in Q1 2026 from $11.4 million in Q1 2025.
- G&A expenses rose to $8.9 million in Q1 2026 from $1.5 million in Q1 2025.
- Enrollment completed for confirmatory Phase 3 Study ‘304’; ongoing for Study ‘306’ in females.